JMP Securities Keeps a Buy Rating on Sarepta Therapeutics (SRPT)

In a report released today, Liisa Bayko from JMP Securities reiterated a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT), with a price target of $270. The company’s shares closed yesterday at $131.34.

According to TipRanks.com, Bayko is a 5-star analyst with an average return of 19.7% and a 47.6% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, DBV Technologies SA – American, and Arbutus Biopharma Corporation.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $198.06, representing a 50.8% upside. In a report issued on October 12, Bernstein also initiated coverage with a Buy rating on the stock with a $170 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $176.50 and a one-year low of $46.07. Currently, Sarepta Therapeutics has an average volume of 1.08M.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.